Overview

This trial has been completed.

Condition parkinson's disease
Treatments cd-ld ir, ipx203 180 mg, ipx203 270 mg, rytary 195 mg, rytary 145 mg
Phase phase 2
Sponsor IMPAX Laboratories, Inc.
Start date November 2015
End date August 2016
Trial size 26 participants
Trial identifier NCT02271503, IPX203-B14-02

Summary

This is a randomized, open-label, rater-blinded, multicenter, 3-treatment, 3 period, single-dose crossover study. Approximately 51 qualified immediate-release (IR) CD-LD-experienced advanced Parkinson's disease patients will be randomized to 1 of 3 dosing sequences.

Objectives:

- Assess the pharmacodynamics and pharmacokinetics (PK) of IPX203 (carbidopa and levodopa) in subjects with advanced Parkinson's disease.

- Characterize the safety of IPX203 in subjects with advanced Parkinson's disease.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model crossover assignment
Primary purpose treatment
Masking investigator, outcomes assessor
Arm
(Other)
Subject received a single dose of IPX203 180 mg and/or IPX203 245mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
cd-ld ir Sinemet
CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
ipx203 180 mg CD-LD ER 180 mg
IPX203 containing 45 mg carbidopa and180 mg levodopa
ipx203 270 mg CD-LD ER 270 mg
IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
rytary 195 mg
Rytary 48.75Mg-195Mg Extended-Release Capsule
rytary 145 mg
Rytary 36.25Mg-145Mg Extended-Release Capsule
(Other)
Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 245mg in Period 3.
cd-ld ir Sinemet
CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
ipx203 180 mg CD-LD ER 180 mg
IPX203 containing 45 mg carbidopa and180 mg levodopa
ipx203 270 mg CD-LD ER 270 mg
IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
rytary 195 mg
Rytary 48.75Mg-195Mg Extended-Release Capsule
rytary 145 mg
Rytary 36.25Mg-145Mg Extended-Release Capsule
(Other)
Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 245mg in Period 2, and a single dose of CD-LD IR in Period 3.
cd-ld ir Sinemet
CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
ipx203 180 mg CD-LD ER 180 mg
IPX203 containing 45 mg carbidopa and180 mg levodopa
ipx203 270 mg CD-LD ER 270 mg
IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
rytary 195 mg
Rytary 48.75Mg-195Mg Extended-Release Capsule
rytary 145 mg
Rytary 36.25Mg-145Mg Extended-Release Capsule

Primary Outcomes

Measure
"Off" time per the Assessment of Subject's Motor State
time frame: Up to 10 hours

Secondary Outcomes

Measure
Duration of effect estimated using the timepoint at which an improvement of at least 4 points in the MDS-UPDRS Part III score from predose is first observed and continuing until the timepoint at which the improvement is no longer observed
time frame: Up to 10 hours
Change from predose value in the number of finger-taps at each timepoint
time frame: Up to 10 hours

Eligibility Criteria

All participants at least 40 years old.

Inclusion Criteria: Male or female subjects diagnosed with idiopathic PD with motor complications, who are currently being treated chronically with stable regimens of CD-LD. Requiring at least 400 mg but not more than 1600 mg LD per day during the waking hours; and at least 100 mg but not more than 250 mg LD from IR CD-LD for the first morning dose. Dosing frequency of IR CD-LD of at least 4 times daily excluding nighttime dosing. Have an average of at least 2 hours per day "off" time during the waking hours and at least 1 hour "off" time per day, based on the PD diary collected for 3 consecutive days prior to Visit 1. Exclusion criteria: Have used first morning dose of controlled-release (CR) CD-LD or Rytary for at least 4 weeks prior to Visit 1. Female subjects who are currently breastfeeding or lactating. Had prior functional neurosurgical treatment for PD (ablation or deep brain stimulation) or if such procedure(s) are planned or anticipated during the study period. Allergic to study drugs History of medical conditions or of a prior surgical procedure that would interfere with LD absorption, such as gastrectomy or small-bowel resection. History of peptic ulcer disease or upper gastrointestinal hemorrhage. History of narrow angle glaucoma. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias; neuroleptic malignant syndrome; or nontraumatic rhabdomyolysis. History of psychosis. Employees or family members of the Investigator, study site, or Sponsor. Subjects who, in the opinion of the clinical investigator, should not participate in the study. Based on clinical assessment, subject does not adequately comprehend the terminology needed to complete the PD diary.

Additional Information

Official title A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease
Description IPX203 contains two different drugs called levodopa and carbidopa in one capsule. - levodopa turns into a material called 'dopamine' in your brain. The dopamine helps to improve the symptoms of your Parkinson's disease. - carbidopa belongs to a group of medicines called 'aromatic amino acid decarboxylase inhibitors'. It helps levodopa work more effectively by slowing the speed at which levodopa is broken down in your body.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by IMPAX Laboratories, Inc..